Advertisement

Topics

Companies Related to "Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)" [Most Relevant Company Matches] RSS

13:14 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)" found in our extensive corporate database of over 50,000 company records.

Showing "Lutonix Drug Coated Balloon Treatment Femoropopliteal Arteries United" Companies 1–25 of 8,800+

Relevant

Lutonix, Inc.

Restenosis is the re-narrowing of an artery experienced by some patients following angioplasty, atherectomy, or stenting. Restenosis is caused by an overgrowth of tissue inside the artery wall at the original treatment site. Restenosis is typically experienced by some patients within the first 6 months of treatment, which most often results in re-intervention or surgery.


Cappella Medical Devices Ltd

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the ...

Shockwave Medical

Shockwave Medical, based in Fremont, Calif., is pioneering Lithoplasty™ technology, a promising breakthrough for the treatment of peripheral and coronary vascular disease and aortic stenosis. Delivered on a standard balloon catheter platform, Lithoplasty combines the calcium disrupting power of lithotripsy with the familiarity and simplicity of a balloon in ...


Vascular Nanotransfer Technologies

Privately held VNT, based in Auburndale, Mass., is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.

Samson Showalter Lepore Vascular Specialists

Our practice is the only medical practice in the Tri-county area dedicated to the treatment of patients with disorders of the veins and arteries, the Vascular System. Unlike most vascular surgical groups, we are also uniquely trained and experienced to offer all forms of diagnosis and therapy including:medications exercise therapy endovascular diagnosis and treatments (Angiography, Balloon angiopl...

Verso Paper Corp.

Based in Memphis, Tennessee, Verso Paper Corp. is a leading North American producer of coated papers, including coated groundwood and coated freesheet, and specialty products. Verso’s paper products are used primarily in media and marketing applications, including magazines, catalogs and commercial printing applications such as high-end advertising br...

The Medicines Company

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

Invatec

Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collab...

Jen-Coat

Jen-Coat was founded in 1972 and supplies the food packaging, medical and industrial markets with a wide range of extrusion laminated, extrusion coated, metalized, and adhesive laminated structures. Products include paper/foil laminations, film/foil laminations, film/film laminations, composite can laminations, coated nonwovens, coated papers, release liners and many other specialty packaging mate...

Medicines Co.

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

Possis Medical

Possis Medical, Inc. is pioneering mechanical thrombectomy, i.e. the rapid, safe and effective removal of blood clots from native arteries and veins, as well as from synthetic and saphenous vein grafts. The Company currently has a portfolio of three FDA indications for use of its AngioJet® Rheolytic™ Thrombectomy System. The system has been used to treat over 250,000 patients in 1,400 locations...

Bangs Laboratories Incorporated

Our new ProActive® protein-coated microspheres are getting rave reviews from customers doing immunoassays, molecular biology and cell work. These generic solid phases dramatically simplify binding to beads, continuing our tradition of supplying only the best microspheres available in the world. (Ask for TechNote #51 for a complete overview and tips on using all of our ProActive® products.) ...

Cappella Medical Devices Limited

Cappella, Inc. develops novel solutions for the treatment of complex coronary artery disease (CAD) - specifically bifurcation disease. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, solution that focuses on treating the sidebranch of diseased coronary arteries first, rather tha...

Xtent

XTENT, Inc. develops customizable drug-eluting stent (DES) systems for the treatment of coronary artery disease. XTENT's customizable DES systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Founded in 2001, XTENT was incubated by The Foundry (Redwood City, CA) and incorpora...

Endologix® Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge...

C2 Therapeutics

C2 Therapeutics was founded in 2007 to address the limitations of current Barrett’s Esophagus treatment options. Headquartered in Redwood City, California, C2 is a privately held company whose C2 Cryoballoon Ablation System sets a new standard for simplicity and cost effectiveness in treating Barrett’s Esophagus. The device is a TTS (through-the-...

Biobusiness.Inc

Based in Szeged, Hungary, Avicor Ltd is a spin-off company of the Biological Research Center of the Hungarian Academy of Sciences. Avicor produces high-density chemical microarrays (Avi-ChemixTM) for fast and parallel hit and target identification in the field of drug discovery. Avicor's core technology is the production and application of chemical microarrays. Avicor uses proprietary surfaces for...

Allurion Technologies

Allurion Technologies is dedicated to helping people transform their health and realize their full potential with products that are safe, effective, affordable, and scalable. The company's flagship product, the Elipse Balloon, is a swallowable, procedureless weight loss device that resides in the stomach, inducing satiety and promoting weight loss. Learn m...

Cardiovascular Systems, Inc.

Cardiovascular Systems Inc., (CSI) (Nasdaq: CSII) based in St. Paul, Minn., is a medical device company focused on providing clinically proven, safe and effective interventional solutions for vascular disease. The company’s Diamondback 360® System removes calcified and fibrotic plaque in small and large peripheral vessels, and addresses many of the...

Esperion

We discover and develop pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body's blood vessels and related organs. We intend to commercialize a novel class of drugs that focus on a new treatment approach we call "HDL Therapy," which is based on our understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of...

Volcano Corporation

Volcano develops, manufactures and commercializes a broad suite of intravascular ultrasound (IVUS) and functional measurement (FM) products that aid in the diagnosis and treatment of vascular and structural heart disease. It has been reported that over 70 million people in the United States have cardiovascular disease. Vascular disease, or atherosclerosis, is caused by the accumulation of fat-lade...

ReShape Medical, Inc.

ReShape Medical® (www.reshapemedical.com) is a medical device manufacturer headquartered in Southern California. The company specializes in a dual-intragastric balloon for weight loss, ReShape Duo®, to be used as an aid in the treatment of obese or overweight patients. ReShape Duo is a non-surgical alternative designed for those who have exhausted th...

NPS Pharmaceuticals

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervous system disorders. History of Successful Drug Discovery NPS has a history of successful drug discovery. With one approved product on the market and several more in development, NPS's discovery capab...

Metactive Medical Inc.

Metactive is developing innovative new medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms, arteries, and veins using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.

Columbia Laboratories, Inc.

Columbia Laboratories, Inc. is focused on developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company's strategy is to fund new development projects through proof of concept, then partner for later-stage clinical development and commercialization. CRINONE® 8% ...


More From BioPortfolio on "Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks